Arrowhead Pharmaceuticals, Inc. (ARWR)

17.96
0.42 2.29
NASDAQ
Prev Close 18.38
Open 18.32
Day Low/High 17.50 / 18.57
52 Wk Low/High 6.12 / 22.39
Volume 976.25K
Exchange NASDAQ
Shares Outstanding 94.21B
Market Cap 1.81B
Div & Yield N.A. (N.A)
Arrowhead To Present At 2015 RBC Capital Markets' Global Healthcare Conference

Arrowhead To Present At 2015 RBC Capital Markets' Global Healthcare Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Arrowhead's chief operating officer Bruce Given, M.

4 Biotech Stocks Under $10 to Trade for Breakouts: Sophiris, Atossa and More

4 Biotech Stocks Under $10 to Trade for Breakouts: Sophiris, Atossa and More

Keep these under-$10 biotech stocks on your breakout trading radar.

Arrowhead Reports Fiscal 2015 First Quarter Financial Results

Arrowhead Reports Fiscal 2015 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2015 first quarter ended December 31, 2014.

Arrowhead To Report Fiscal 2015 First Quarter Financial Results

Arrowhead To Report Fiscal 2015 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2015 first quarter ended December...

Insider Trading Alert - CFX, ARWR And FMI Traded By Insiders

Insider Trading Alert - CFX, ARWR And FMI Traded By Insiders

Stocks with insider trader activity include CFX, ARWR and FMI

Arrowhead Research (ARWR) Stock Plummets Today After FDA Partial Clinical Hold

Arrowhead Research (ARWR) Stock Plummets Today After FDA Partial Clinical Hold

Shares of Arrowhead Research (ARWR) plunged in morning trading Monday after the FDA instituted a partial clinical hold on the drug developer's potential hepatitis B treatment.

Arrowhead Provides Update On IND For ARC-520 Phase 2b Study

Arrowhead Provides Update On IND For ARC-520 Phase 2b Study

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the U.

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Today's Weak On High Volume Stock: Arrowhead Research (ARWR)

Today's Weak On High Volume Stock: Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

Arrowhead Research (ARWR) Is Strong On High Volume Today

Arrowhead Research (ARWR) Is Strong On High Volume Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know

To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.

Arrowhead Files IND For RNAi Therapeutic ARC-520 To Begin Phase 2b Multiple-Dose Studies In Chronic Hepatitis B Patients

Arrowhead Files IND For RNAi Therapeutic ARC-520 To Begin Phase 2b Multiple-Dose Studies In Chronic Hepatitis B Patients

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it submitted an Investigational New Drug (IND) application to the U.

Arrowhead Research (ARWR) Showing Signs Of Perilous Reversal Today

Arrowhead Research (ARWR) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

CORRECTING and REPLACING Arrowhead Appoints Patrick O'Brien as General Counsel

CORRECTING and REPLACING Arrowhead Appoints Patrick O'Brien as General Counsel

Arrowhead Research Corporation corrects its press release issued on December 4, 2014, to correct the statement regarding "inducement" grants.

INVESTOR ALERT: Class Action Lawsuit Against Arrowhead Research Corporation Announced By Law Offices Of Howard G. Smith

INVESTOR ALERT: Class Action Lawsuit Against Arrowhead Research Corporation Announced By Law Offices Of Howard G. Smith

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of purchasers of the common stock of Arrowhead ...

INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Arrowhead Research Corporation

INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Arrowhead Research Corporation

Glancy Binkow & Goldberg LLP reminds investors of Arrowhead Research Corporation ("Arrowhead" or the "Company") (NASDAQ:ARWR) that purchasers of Arrowhead common stock between August 12, 2014 and October...

Arrowhead Reports Fiscal 2014 Year End Financial Results

Arrowhead Reports Fiscal 2014 Year End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 fourth quarter and year ended September 30, 2014.

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against Arrowhead Research Corp. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 9, 2014

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against Arrowhead Research Corp. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 9, 2014

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Arrowhead Research Corp.

SHAREHOLDER ALERT: Investigation On Behalf Of Arrowhead Research Corporation Investors Announced By Law Offices Of Howard G. Smith

SHAREHOLDER ALERT: Investigation On Behalf Of Arrowhead Research Corporation Investors Announced By Law Offices Of Howard G. Smith

Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Arrowhead Research Corporation ("Arrowhead" or the "Company") (NASDAQ:ARWR).

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on...

Arrowhead To Report Fiscal 2014 Fourth Quarter And Year End Financial Results

Arrowhead To Report Fiscal 2014 Fourth Quarter And Year End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 fourth quarter and year...

Arrowhead Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT

Arrowhead Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a Phase 1 clinical trial of...

ARWR January 2017 Options Begin Trading

ARWR January 2017 Options Begin Trading

Investors in Arrowhead Research Corp saw new options become available today, for the January 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead To Present At Upcoming Conferences

Arrowhead To Present At Upcoming Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the Company will present at upcoming investor and scientific conferences.

Arrowhead Research Stock Sees Short Interest Make 10% Move

Arrowhead Research Stock Sees Short Interest Make 10% Move

The most recent short interest data has been released by the NASDAQ for the 10/31/2014 settlement date, which shows a 1,228,584 share increase in total short interest for Arrowhead Research Corp , to 13,404,343, an increase of 10.09% since 10/15/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Arrowhead Presents Data On ARC-520 And ARC-AAT At AASLD The Liver Meeting® 2014

Arrowhead Presents Data On ARC-520 And ARC-AAT At AASLD The Liver Meeting® 2014

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that initial data from the ongoing Phase 2a study of ARC-520, its RNAi therapeutic...

Super Important Biotech and Drug Stock Events for November

Super Important Biotech and Drug Stock Events for November

A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on...

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

TheStreet Quant Rating: D (Sell)